Research Programs - Results



By working closely with researchers, clinicians and our partners in the biotech and pharmaceutical industry, we helped bring multiple myeloma patients four new treatments that are extending lives around the globe. We are now at a turning point where we have the knowledge, the team and the tools to build upon this success and advance the next generation of treatments.

We are reaching incredible milestones in advancing our innovative research portfolio of basic science, validation, and clinical trials programs to ensure that better, more effective treatments are brought to patients as soon as possible.

Basic Science


Our Multiple Myeloma Genomics Initiative – a cutting-edge collaboration between the Multiple Myeloma Research Consortium (MMRC), the Broad Institute, and TGen — recently became the first to sequence the multiple myeloma whole genome in its entirety. Findings from this exciting research program, made possible only with tissue samples from the MMRC Tissue Bank, will be used to identify key targets for new treatments.

The Multiple Myeloma Genomics Initiative has also just completed two other high resolution genomics profiling studies performed at TGen on the full Reference Collection of 250 multiple myeloma patients’ tumor tissue from the MMRC Tissue Bank.

These data were posted in the world’s only myeloma-specific data portal in near real-time to ensure that scientists worldwide have access to cutting edge findings as soon as possible.

Validation


Only a fraction of compounds are shown to be effective in clinical trials and eventually approved by the FDA. To increase the likelihood of success, our Validation Team and MMRF Grantees have made significant progress in screening and prioritizing new compounds and combinations.

Clinical


As an extension of the MMRF’s mission, Founder and CEO Kathy Giusti established in 2004 the Multiple Myeloma Research Consortium (MMRC), to accelerate Phase I and Phase II clinical trials so that new treatments could be brought to patients faster. To date, this unique collaborative model, now comprised of 16 academic research centers and leadership in Norwalk, Conn., has advanced more than 30 clinical trials with industry partners, including Novartis, Celgene, Merck, and Proteolix. Data show that recent trials conducted through the MMRC were opened an average of 30 to 40 percent faster than the industry standard.

The MMRF’s Biotech Investment Award, has also achieved impressive results. This milestone-driven program awards funding to biotech companies to support early-stage drug development of novel compounds and approaches that show potential in treating multiple myeloma. To date, BIA has awarded nearly $10 million to several companies; compounds supported by BIA are now in clinical trials through the MMRC.